CSL Banks Big on VarmX’s Bleeding Control Drug-What It Means Globally
Australia’s CSL Ltd has made headlines with a bold biotech move: it’s put down US$117 million upfront for exclusive option rights to acquire Dutch biotech firm VarmX pending success in…
